Genomics-Driven Trials Built To Be Fast And Flexible
Executive Summary
Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.
You may also be interested in...
Pediatric Oncology Advances Could Prompt More FDA-Required Studies
Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.
Pediatric Oncology Advances Could Prompt More FDA-Required Studies
Findings being presented at ASCO next month could signify major increase in targets relevant to pediatric oncology, meaning sponsors should prepare for more US FDA-required studies under the RACE for Children legislation.
MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations
The adaptive trial design will help test smaller subpopulations and could lead to more effective and cost-efficient treatment strategies.